Analyst Price Targets — STE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 28, 2026 10:34 am | Patrick Wood | UBS | $275.00 | $218.40 | TheFly | Steris initiated with a Buy at UBS |
| May 21, 2026 12:59 pm | Jason Bednar | Piper Sandler | $270.00 | $216.18 | StreetInsider | Piper Sandler: 'Is now the time to buy STERIS (STE)?' |
| May 13, 2026 10:37 am | Brett Fishbin | KeyBanc | $269.00 | $210.85 | TheFly | Steris price target lowered to $269 from $291 at KeyBanc |
| October 24, 2024 3:23 am | Jason Bednar | Piper Sandler | $260.00 | $221.15 | StreetInsider | Piper Sandler Upgrades STERIS (STE) to Overweight |
| September 3, 2024 6:28 am | Brett Fishbin | KeyBanc | $265.00 | $241.10 | TheFly | Steris price target raised to $265 from $255 at KeyBanc |
| May 10, 2024 8:20 am | Jason Bednar | Piper Sandler | $225.00 | $225.95 | StreetInsider | STERIS (STE) PT Raised to $225 at Piper Sandler |
| April 4, 2024 4:23 am | Mike Polark | Wolfe Research | $245.00 | $216.65 | StreetInsider | STERIS (STE) PT Raised to $245 at Wolfe Research |
Latest News for STE
Dublin, Ireland, Sept. 01, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will participate in the Morgan Stanley Healthcare Conference in New York City on Tuesday, September 15, 2026.
STE is betting $600 million on a new chemistry center to boost capacity and efficiency, but higher spending and execution risks loom.
STE enters fiscal 2027 with solid growth, recurring healthcare demand and better margins, but tariffs and investment needs temper the valuation case.
STERIS (NYSE: STE) reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina. Total reported revenue increased 7% from the prior-year quarter, while constant-currency organic revenue rose 6%, driven by volume growth and 190
STERIS NYSE: STE reported first-quarter fiscal 2027 revenue growth and higher earnings, while maintaining its full-year outlook and outlining a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.